Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)
Conditions
Interventions
40 mg Rifaximin SSD once daily
40 mg Rifaximin SSD twice daily
+3 more
Locations
34
United States
Bausch Health Site 18
Corona del Mar, California, United States
Bausch Health Site 15
Los Angeles, California, United States
Bausch Health Site 19
Los Angeles, California, United States
Bausch Health Site 04
San Francisco, California, United States
Bausch Health Site 13
Bristol, Connecticut, United States
Bausch Health Site 08
Miami, Florida, United States
Start Date
September 13, 2018
Primary Completion Date
March 12, 2020
Completion Date
March 12, 2020
Last Updated
April 13, 2023
NCT06483737
NCT03585257
NCT01966419
Lead Sponsor
Bausch Health Americas, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions